JPH09500362A - 断続的なインターロイキン−2療法による免疫強化 - Google Patents
断続的なインターロイキン−2療法による免疫強化Info
- Publication number
- JPH09500362A JPH09500362A JP6525746A JP52574694A JPH09500362A JP H09500362 A JPH09500362 A JP H09500362A JP 6525746 A JP6525746 A JP 6525746A JP 52574694 A JP52574694 A JP 52574694A JP H09500362 A JPH09500362 A JP H09500362A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- therapy
- patients
- infusion
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.免疫不全により特徴づけられる疾患を治療するための方法において用いられ る製剤中のある量IL-2の使用において、 (A)量が、そのような不全を患う患者のヘルパー/インデューサーT細胞機能 のレベルを増加させるのに十分であり、 そして、 (B)患者は、各注入は1日から2週間の期間にわたる連続的な注入であり連続 注入は少なくとも4週間の期間で隔てられた、断続的に行われる一連の注入でIL- 2を投与される、IL-2の使用。 2.量が患者のCD4 T細胞機能を増加させるのに十分である請求の範囲1記載の 使用。 3.量が患者のIL-2レセプターの発現を増加させるのに十分である請求の範囲 1記載の使用。 4.各注入が1.8から24MU/日までのIL-2の用量を含む請求の範囲1記載の使用 。 5.各注入の期間がおよそ5日である請求の範囲4記載の使用。 6.疾患が病原体による患者の感染により特徴づけられる請求の範囲1記載の 使用において、病原体に対して起こる細胞性免疫反応が患者の病原体に対する特 異的な免疫機構に関連したものである使用。 7.患者が免疫系不全である患者の二次感染を含む請求の範囲6記載の使用。 8.(i)患者に注入する溶液を保持するのに適した容器、(ii)IL-2用量が約 1.8から約24MUである、薬学的に許容される担体中にIL-2を含む液剤、および(ii i)免疫不全または感染症を患う患者に断続的に行われる一連の投与により製剤を 投与するための説明書において、患者が約5日間の期間にわたりその容量の連続 注入を受ける説明書、を含む物の組み合わせ。 9.説明書がさらに、投与の前にまたは同時に療法を適用することを指示し、 療法が特異的な疾患を標的としている請求の範囲8記載の組み合わせ。 10.療法が抗レトロウイルス療法である請求の範囲9記載の組み合わせ。 11.抗レトロウイルス療法が患者へのジドブジン投与を含む請求の範囲10 記 載の組み合わせ。 12.(i)患者に注入する溶液を保持するのに適した容器、(ii)IL-2用量が 約1.8から約24MUである、薬学的に許容される担体中にIL-2を含む液剤、および( iii)患者の免疫系が活性化される製剤を患者に投与し、そしてリンパ球のインサ イチュー形質転換を起こすレトロウイルスベクターを患者に投与することについ ての説明書、を含む物の組み合わせ。 13.説明書が、IL-2注入期間中の適当な時点にレトロウイルスベクターを投 与することを指示する請求の範囲16記載の組み合わせ。 14.説明書が、レトロウイルスベクターがIL-2投与の4日目から7日目に投与 されることを指示する請求の範囲12記載の組み合わせ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/063,315 | 1993-05-19 | ||
US08/063,315 US5419900A (en) | 1993-05-19 | 1993-05-19 | Immunologic enhancement with intermittent interleukin-2 therapy |
PCT/US1994/005397 WO1994026293A1 (en) | 1993-05-19 | 1994-05-19 | Immunologic enhancement with intermittent interleukin-2 therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09500362A true JPH09500362A (ja) | 1997-01-14 |
JP4275193B2 JP4275193B2 (ja) | 2009-06-10 |
Family
ID=22048393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52574694A Expired - Lifetime JP4275193B2 (ja) | 1993-05-19 | 1994-05-19 | 断続的なインターロイキン−2療法による免疫強化 |
Country Status (11)
Country | Link |
---|---|
US (3) | US5419900A (ja) |
EP (1) | EP0702560B1 (ja) |
JP (1) | JP4275193B2 (ja) |
AT (1) | ATE208206T1 (ja) |
AU (1) | AU691504B2 (ja) |
CA (1) | CA2163219A1 (ja) |
DE (1) | DE69428992T2 (ja) |
DK (1) | DK0702560T3 (ja) |
ES (1) | ES2167370T3 (ja) |
PT (1) | PT702560E (ja) |
WO (1) | WO1994026293A1 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
US5696079A (en) * | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
EP0862651A2 (en) * | 1995-10-16 | 1998-09-09 | Chiron Corporation | Method of screening for factors that modulate gene expression |
KR100220645B1 (ko) * | 1997-07-04 | 1999-09-15 | 구광시 | 벤젠유도체의 제조방법 |
CA2310805A1 (en) * | 1997-11-24 | 1999-06-03 | Johnson T. Wong | Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
EP1141314A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
ES2299276T3 (es) * | 1998-12-31 | 2008-05-16 | Novartis Vaccines And Diagnostics, Inc. | Polipeptidos env del vih modificados. |
EP1141313A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US6921530B1 (en) * | 1999-09-24 | 2005-07-26 | Cornell Research Foundation, Inc. | Low dose IL-2 for potentiation of immunity |
WO2002020052A1 (fr) * | 2000-09-08 | 2002-03-14 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
FR2813793B1 (fr) * | 2000-09-08 | 2003-01-24 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
US6579521B2 (en) * | 2000-10-20 | 2003-06-17 | Chiron Corporation | Methods of therapy for HIV infection |
US20030003074A1 (en) * | 2001-06-14 | 2003-01-02 | Macromed, Inc. | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
US20060159657A1 (en) * | 2001-06-14 | 2006-07-20 | Macromed, Incorporated | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
CA2452015C (en) | 2001-07-05 | 2012-07-03 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US20030198621A1 (en) * | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
WO2003015697A2 (en) * | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
AU2002316578A1 (en) * | 2001-08-31 | 2003-03-18 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
RU2201762C1 (ru) * | 2001-10-09 | 2003-04-10 | Свадовский Александр Игоревич | Способ лечения внутримозговой опухоли головного мозга |
WO2005043155A1 (en) | 2003-10-21 | 2005-05-12 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
US20070098685A1 (en) * | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
WO2008039874A2 (en) | 2006-09-26 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
WO2008039969A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
PL2328923T3 (pl) | 2008-09-02 | 2016-06-30 | Cedars Sinai Medical Center | Epitopy CD133 |
PL2427485T3 (pl) | 2009-05-07 | 2017-10-31 | Immunocellular Therapeutics Ltd | Epitopy CD133 |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
CN110511278A (zh) | 2012-05-07 | 2019-11-29 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
CA2898474A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
JP6941561B2 (ja) | 2014-10-09 | 2021-09-29 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 免疫障害を処置するための複数の可変il−2用量レジメン |
KR102653906B1 (ko) | 2020-01-14 | 2024-04-03 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
US4863730A (en) | 1986-03-21 | 1989-09-05 | Cenfold Holdings, S.A. | Immunotherapy for AIDS patients |
US4868157A (en) | 1987-10-05 | 1989-09-19 | Merck & Co., Inc. | Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use |
US4866157A (en) * | 1987-11-10 | 1989-09-12 | Sugio Otani | Thermosetting aromatic resin composition |
DE3818054C2 (de) * | 1988-05-27 | 1994-02-17 | Biotest Pharma Gmbh | Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen |
FR2653020B1 (fr) * | 1989-10-17 | 1993-03-26 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies. |
US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
ATE120860T1 (de) | 1990-01-26 | 1995-04-15 | Washington Res Found | Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten. |
FR2660863B1 (fr) * | 1990-04-17 | 1994-01-21 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre. |
US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
US5696079A (en) | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
-
1993
- 1993-05-19 US US08/063,315 patent/US5419900A/en not_active Expired - Lifetime
-
1994
- 1994-05-19 AT AT94920673T patent/ATE208206T1/de active
- 1994-05-19 WO PCT/US1994/005397 patent/WO1994026293A1/en active IP Right Grant
- 1994-05-19 ES ES94920673T patent/ES2167370T3/es not_active Expired - Lifetime
- 1994-05-19 AU AU71377/94A patent/AU691504B2/en not_active Expired
- 1994-05-19 EP EP94920673A patent/EP0702560B1/en not_active Expired - Lifetime
- 1994-05-19 DK DK94920673T patent/DK0702560T3/da active
- 1994-05-19 JP JP52574694A patent/JP4275193B2/ja not_active Expired - Lifetime
- 1994-05-19 PT PT94920673T patent/PT702560E/pt unknown
- 1994-05-19 DE DE69428992T patent/DE69428992T2/de not_active Expired - Lifetime
- 1994-05-19 CA CA002163219A patent/CA2163219A1/en not_active Withdrawn
-
1997
- 1997-09-02 US US08/922,218 patent/US6190656B1/en not_active Expired - Lifetime
-
2000
- 2000-08-09 US US09/635,286 patent/US6548055B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1994026293A1 (en) | 1994-11-24 |
CA2163219A1 (en) | 1994-11-24 |
ATE208206T1 (de) | 2001-11-15 |
JP4275193B2 (ja) | 2009-06-10 |
PT702560E (pt) | 2002-04-29 |
AU7137794A (en) | 1994-12-12 |
EP0702560A1 (en) | 1996-03-27 |
US6548055B1 (en) | 2003-04-15 |
ES2167370T3 (es) | 2002-05-16 |
AU691504B2 (en) | 1998-05-21 |
DK0702560T3 (da) | 2002-02-25 |
US6190656B1 (en) | 2001-02-20 |
EP0702560B1 (en) | 2001-11-07 |
DE69428992D1 (de) | 2001-12-13 |
US5419900A (en) | 1995-05-30 |
DE69428992T2 (de) | 2002-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4275193B2 (ja) | 断続的なインターロイキン−2療法による免疫強化 | |
Lane et al. | Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma | |
Folks et al. | Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line | |
Klatzmann et al. | HIV infection: facts and hypotheses | |
Cousins et al. | Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye | |
Sztein et al. | Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes | |
Poli et al. | Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. | |
Cianciolo et al. | Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation | |
Andersson et al. | Human interleukin 6 and tumor necrosis factor α production studied at a single‐cell level | |
FAIST et al. | Immunomodulatory therapy with thymopentin and indomethacin | |
JP2006312640A (ja) | T細胞活性化 | |
US5696079A (en) | Immunologic enhancement with intermittent interleukin-2 therapy | |
Gupta et al. | Detection of a human intracisternal retroviral particle associated with CD4+ T-cell deficiency. | |
Ellman et al. | Mechanisms involved in the antileukemic effect of immunocompetent allogeneic lymphoid cell transfer | |
JPH01500591A (ja) | 実質的に純粋な細胞毒性トリガー因子 | |
US20020172687A1 (en) | Anti-Viral Treatment With Pertussis Toxin B Oligomer | |
Stein et al. | A longitudinal study of patients with hemophilia: immunologic correlates of infection with HTLV-III/LAV and other viruses | |
Chosich et al. | Suppression of diabetes mellitus in the non-obese diabetic (NOD) mouse by an autoreactive (anti-IA g7) islet-derived CD4+ T-cell line | |
Onji et al. | Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis. | |
Caruso et al. | Characterization of T cell subsets involved in the production of IFN-γ in asymptomatic HIV-infected patients | |
US20030180254A1 (en) | Immunologic enhancement with intermittent interleukin-2 therapy | |
Tsoukas et al. | Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate. | |
AU699217B2 (en) | Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic disorders, and graft rejection | |
Michelini-Norris et al. | Involvement of HLA-DR+ large granular lymphocytes in the induction of tumor necrosis factor by Mycobacterium avium-intracellulare complex | |
Stefanovic et al. | The role of CD4+ lymphocytes in the activation of non-specific suppressor cells by antigen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070110 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070417 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071226 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080221 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081210 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090304 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120313 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120313 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130313 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130313 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140313 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |